EXACT
Research type
Research Study
Full title
EXACT – understanding immunE-related toXicities by multifACeT profiling
IRAS ID
238200
Contact name
Samra Turajlic
Contact email
Sponsor organisation
The Royal Marsden NHS Foundation Trust
Duration of Study in the UK
6 years, 0 months, 1 days
Research summary
This study is aiming to describe clinical and biological markers for side effects of cancer treatment with immunotherapy - immune related adverse events (irAE). Immunotherapy has become an important pillar of cancer treatment across many cancer types and can improve the outcome of cancer treatment for a notable number of patients. Side effects from this treatment can affect a broad variety of organs and tissues in the body and vary from mild to - less frequent - severe and in a subset of patients can even lead to death. Currently there is a lack of understanding how we can predict which patient is at a higher risk of developing an irAE, which irAE it will be and with which severity it will occur. Clinical determinants, such as age, BMI, previous medical history etc., and biological determinants, such as composition of immune cells etc., could help predict individual irAE risk profiles better. In this study we will collect clinical data and biological samples from patients undergoing immunotherapy before treatment start, during treatment, at development of an irAE, during an irAE and at resolution of irAE as well as during follow up after treatment. We aim to describe these determinants and how they correlate with irAEs in general, specific irAEs, severity of irAE and response to irAE treatment.
REC name
West Midlands - Black Country Research Ethics Committee
REC reference
21/WM/0251
Date of REC Opinion
22 Nov 2021
REC opinion
Further Information Favourable Opinion